4-Oxazolidinecarboxamide, 5-methyl-N-[(1S)-2-[(2R)-2-methyl-1-pyrrolidinyl]-2-oxo-1-(4-thiazolylmethyl)ethyl]-2-oxo-, (4S,5S)- manufacturers
- Rovatirelin
-
- $223.00
-
2026-07-27
- CAS:204386-76-5
- Purity: 99.84%
- Supply Ability: 10g
|
| | 4-Oxazolidinecarboxamide, 5-methyl-N-[(1S)-2-[(2R)-2-methyl-1-pyrrolidinyl]-2-oxo-1-(4-thiazolylmethyl)ethyl]-2-oxo-, (4S,5S)- Basic information |
| | 4-Oxazolidinecarboxamide, 5-methyl-N-[(1S)-2-[(2R)-2-methyl-1-pyrrolidinyl]-2-oxo-1-(4-thiazolylmethyl)ethyl]-2-oxo-, (4S,5S)- Chemical Properties |
| Boiling point | 755.1±60.0 °C(Predicted) | | density | 1.315±0.06 g/cm3(Predicted) | | pka | 11.03±0.60(Predicted) |
| | 4-Oxazolidinecarboxamide, 5-methyl-N-[(1S)-2-[(2R)-2-methyl-1-pyrrolidinyl]-2-oxo-1-(4-thiazolylmethyl)ethyl]-2-oxo-, (4S,5S)- Usage And Synthesis |
| Uses | Rovatirelin is an orally active thyrotropin-releasing hormone (TRH) analog. Rovatirelin binds to the human TRH receptor with a Ki value of 702 nM. Rovatirelin can be used to study spinocerebellar degeneration (SCD) [1]. | | References | [1] Ijiro T, et al. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system. Eur J Pharmacol. 2015 Aug 15;761:413-22. DOI:10.1016/j.ejphar.2015.05.047 |
| | 4-Oxazolidinecarboxamide, 5-methyl-N-[(1S)-2-[(2R)-2-methyl-1-pyrrolidinyl]-2-oxo-1-(4-thiazolylmethyl)ethyl]-2-oxo-, (4S,5S)- Preparation Products And Raw materials |
|